Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence

IF 28.5 1区 医学 Q1 ONCOLOGY Nature cancer Pub Date : 2025-01-30 DOI:10.1038/s43018-024-00891-1
Julius Keyl, Philipp Keyl, Grégoire Montavon, René Hosch, Alexander Brehmer, Liliana Mochmann, Philipp Jurmeister, Gabriel Dernbach, Moon Kim, Sven Koitka, Sebastian Bauer, Nikolaos Bechrakis, Michael Forsting, Dagmar Führer-Sakel, Martin Glas, Viktor Grünwald, Boris Hadaschik, Johannes Haubold, Ken Herrmann, Stefan Kasper, Rainer Kimmig, Stephan Lang, Tienush Rassaf, Alexander Roesch, Dirk Schadendorf, Jens T. Siveke, Martin Stuschke, Ulrich Sure, Matthias Totzeck, Anja Welt, Marcel Wiesweg, Hideo A. Baba, Felix Nensa, Jan Egger, Klaus-Robert Müller, Martin Schuler, Frederick Klauschen, Jens Kleesiek
{"title":"Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence","authors":"Julius Keyl, Philipp Keyl, Grégoire Montavon, René Hosch, Alexander Brehmer, Liliana Mochmann, Philipp Jurmeister, Gabriel Dernbach, Moon Kim, Sven Koitka, Sebastian Bauer, Nikolaos Bechrakis, Michael Forsting, Dagmar Führer-Sakel, Martin Glas, Viktor Grünwald, Boris Hadaschik, Johannes Haubold, Ken Herrmann, Stefan Kasper, Rainer Kimmig, Stephan Lang, Tienush Rassaf, Alexander Roesch, Dirk Schadendorf, Jens T. Siveke, Martin Stuschke, Ulrich Sure, Matthias Totzeck, Anja Welt, Marcel Wiesweg, Hideo A. Baba, Felix Nensa, Jan Egger, Klaus-Robert Müller, Martin Schuler, Frederick Klauschen, Jens Kleesiek","doi":"10.1038/s43018-024-00891-1","DOIUrl":null,"url":null,"abstract":"Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles. xAI determined the prognostic contribution of each clinical marker at the patient level and identified 114 key markers that accounted for 90% of the neural network’s decision process. Moreover, xAI enabled us to uncover 1,373 prognostic interactions between markers. Our approach was validated in an independent cohort of 3,288 patients with lung cancer from a US nationwide electronic health record-derived database. These results show the potential of xAI to transform the assessment of clinical variables and enable personalized, data-driven cancer care. Keyl et al. present an explainable artificial intelligence model-based real-world data analysis from over 15,000 patients across 38 cancer types, identified key prognostic marker interactions, and confirmed these in an external lung cancer cohort.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 2","pages":"307-322"},"PeriodicalIF":28.5000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43018-024-00891-1.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-024-00891-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles. xAI determined the prognostic contribution of each clinical marker at the patient level and identified 114 key markers that accounted for 90% of the neural network’s decision process. Moreover, xAI enabled us to uncover 1,373 prognostic interactions between markers. Our approach was validated in an independent cohort of 3,288 patients with lung cancer from a US nationwide electronic health record-derived database. These results show the potential of xAI to transform the assessment of clinical variables and enable personalized, data-driven cancer care. Keyl et al. present an explainable artificial intelligence model-based real-world data analysis from over 15,000 patients across 38 cancer types, identified key prognostic marker interactions, and confirmed these in an external lung cancer cohort.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用多模态真实世界数据和可解释的人工智能解码泛癌症治疗结果。
尽管精准肿瘤学取得了进步,但临床决策仍然依赖于有限的变量和专家知识。为了解决这一限制,我们将多模态真实世界数据和可解释的人工智能(xAI)结合起来,引入人工智能衍生(AID)标记物,用于临床决策支持。我们使用xAI对38个实体癌症实体的15,726名患者的结果进行解码,这些结果基于350个标记,包括临床记录、图像衍生的身体成分和突变肿瘤谱。xAI确定了每个临床标志物在患者水平上对预后的贡献,并确定了114个关键标志物,这些标志物占神经网络决策过程的90%。此外,xAI使我们能够发现1,373个标志物之间的预后相互作用。我们的方法在来自美国全国电子健康记录衍生数据库的3288例肺癌患者的独立队列中得到了验证。这些结果显示了xAI在改变临床变量评估和实现个性化、数据驱动的癌症治疗方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature cancer
Nature cancer Medicine-Oncology
CiteScore
31.10
自引率
1.80%
发文量
129
期刊介绍: Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.
期刊最新文献
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. A functional map of m6A sites in cancer. The genomic model P-CARE enables precision prostate cancer screening in a national healthcare system. AI for breast cancer screening. Diagnostic accuracy, fairness and clinical implementation of AI for breast cancer screening: results of multicenter retrospective and prospective technical feasibility studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1